Published in J Cancer Res Clin Oncol on January 01, 1983
Identification of an Epstein-Barr virus-coded thymidine kinase. EMBO J (1986) 1.31
Identification of APC gene mutations in Italian adenomatous polyposis coli patients by PCR-SSCP analysis. Am J Hum Genet (1993) 1.16
Epstein-Barr virus small RNA (EBER) genes: differential regulation during lytic viral replication. J Virol (1998) 1.03
Epstein-Barr virus-encoded EBNA1 enhances RNA polymerase III-dependent EBER expression through induction of EBER-associated cellular transcription factors. Mol Cancer (2010) 0.84
The establishment of cell lines from chronic B cell leukaemias: evidence of leukaemic origin by karyotypic abnormalities and Ig gene rearrangement. Clin Exp Immunol (1988) 0.83
Disruption of the MMAC1/PTEN gene by deletion or mutation is a frequent event in malignant melanoma. Cancer Res (1997) 2.98
Nonsense suppressors of Saccharomyces cerevisiae can be generated by mutation of the tyrosine tRNA anticodon. Nature (1976) 2.07
Biosynthesis of the beta and beta' subunits of RNA polymerase in Escherichia coli. J Mol Biol (1973) 2.03
Properties of the K562 cell line, derived from a patient with chronic myeloid leukemia. Int J Cancer (1976) 1.97
Replication of the F'lac sex factor in the cell cycle of Escherichia coli. Mol Gen Genet (1971) 1.92
Purification of zymogen to plasminogen activator from human glioblastoma cells by affinity chromatography with monoclonal antibody. Biochemistry (1982) 1.85
Somatic mutation of the Peutz-Jeghers syndrome gene, LKB1/STK11, in malignant melanoma. Oncogene (1999) 1.59
The p16-cyclin D/Cdk4-pRb pathway as a functional unit frequently altered in melanoma pathogenesis. Cancer Res (1996) 1.55
Hybridization of a myeloid leukemia-derived human cell line (K562) with a human Burkitt's lymphoma line (P3HR-1). J Natl Cancer Inst (1980) 1.53
Inducibility of the Epstein-Barr virus (EBV) cycle and surface marker properties of EBV-negative lymphoma lines and their in vitro EBV-converted sublines. Int J Cancer (1976) 1.41
Somatic Fas mutations in non-Hodgkin's lymphoma: association with extranodal disease and autoimmunity. Blood (1998) 1.41
Higher-order structure of human mitotic chromosomes. Proc Natl Acad Sci U S A (1977) 1.38
Isolation of novel HLA-DR restricted potential tumor-associated antigens from the melanoma cell line FM3. Cancer Res (1997) 1.38
Identification of an Epstein-Barr virus-coded thymidine kinase. EMBO J (1986) 1.31
Alterations of the MMAC1/PTEN gene in lymphoid malignancies. Blood (1998) 1.27
Accumulation of identical T cells in melanoma and vitiligo-like leukoderma. J Invest Dermatol (1999) 1.24
Characterization of a human ovarian teratocarcinoma-derived cell line. Int J Cancer (1980) 1.19
Phosphorylated peptides can be transported by TAP molecules, presented by class I MHC molecules, and recognized by phosphopeptide-specific CTL. J Immunol (1999) 1.19
Plasminogen and tissue-type plasminogen activator bind to immobilized fibronectin. J Biol Chem (1985) 1.15
Tumour-specific MHC-class-II-restricted responses after in vitro sensitization to synthetic peptides corresponding to gp100 and Annexin II eluted from melanoma cells. Cancer Immunol Immunother (1998) 1.15
Spontaneous human squamous cell carcinomas are killed by a human cytotoxic T lymphocyte clone recognizing a wild-type p53-derived peptide. Proc Natl Acad Sci U S A (1996) 1.14
Mutation and allelic loss of the PTEN/MMAC1 gene in primary and metastatic melanoma biopsies. J Invest Dermatol (2000) 1.12
Single-step DGGE-based mutation scanning of the p53 gene: application to genetic diagnosis of colorectal cancer. Hum Mutat (1997) 1.09
Transformation induced by Epstein-Barr virus and the role of the nuclear antigen. Cold Spring Harb Symp Quant Biol (1980) 1.08
HLA antigen expression at the single cell level on a K562 X B cell hybrid: an analysis with monoclonal antibodies using bacterial binding assays. Somatic Cell Genet (1982) 1.06
Presentation of cytosolic glycosylated peptides by human class I major histocompatibility complex molecules in vivo. J Exp Med (1999) 1.05
Inactive proenzyme to tissue-type plasminogen activator from human melanoma cells, identified after affinity purification with a monoclonal antibody. EMBO J (1984) 1.03
Ecto-ATP diphosphohydrolase/CD39 is overexpressed in differentiated human melanomas. FEBS Lett (1998) 1.01
In situ T cells in melanoma. Cancer Immunol Immunother (1999) 1.01
Two-site time-resolved immunofluorometric assay of human insulin. Clin Chem (1986) 1.01
Poor correspondence between predicted and experimental binding of peptides to class I MHC molecules. Tissue Antigens (2000) 1.00
Monoclonal antibody to human 66,000 molecular weight plasminogen activator from melanoma cells. Specific enzyme inhibition and one-step affinity purification. EMBO J (1983) 0.99
Expression of basic fibroblast growth factor and vascular endothelial growth factor in primary and metastatic melanoma from the same patients. Melanoma Res (1999) 0.98
Detection and characterization of alpha-beta-T-cell clonality by denaturing gradient gel electrophoresis (DGGE). Biotechniques (1998) 0.97
Monoclonal antibody that specifically inhibits a human Mr 52,000 plasminogen-activating enzyme. Proc Natl Acad Sci U S A (1982) 0.97
In situ T cell responses against melanoma comprise high numbers of locally expanded T cell clonotypes. J Immunol (1999) 0.96
Multiple mechanisms of immune evasion can coexist in melanoma tumor cell lines derived from the same patient. Cancer Immunol Immunother (2001) 0.96
Enzyme-linked immunosorbent assay for human urokinase-type plasminogen activator and its proenzyme using a combination of monoclonal and polyclonal antibodies. J Immunoassay (1986) 0.96
Somatic cell hybrids between human lymphoma lines. III. Surface markers. Int J Cancer (1977) 0.96
The V410I (G1228A) variant of the caspase-10 gene is a common polymorphism of the Danish population. Blood (2000) 0.95
Monoclonal antibodies to K88ab, K88ac and K88ad fimbriae from enterotoxigenic Escherichia coli. Microb Pathog (1986) 0.95
Human-human hybridomas and human monoclonal antibodies obtained by fusion of lymph node lymphocytes from breast cancer patients. Cancer Res (1988) 0.95
Clonal T cell responses in tumor infiltrating lymphocytes from both regressive and progressive regions of primary human malignant melanoma. J Clin Invest (1996) 0.94
Cell cycle arrest by the PTEN tumor suppressor is target cell specific and may require protein phosphatase activity. Exp Cell Res (2000) 0.92
Activation of preexisting T cell clones by targeted interleukin 2 therapy. Proc Natl Acad Sci U S A (1998) 0.92
Regulation of B lymphocyte replication and maturation. J Cell Biochem (1982) 0.92
Somatic cell hybrids between human lymphoma lines. IV. Establishment and characterization of a P3HR-1/Daudi hybrid. Int J Cancer (1978) 0.91
Pattern of replication of a colicin factor during the cell cycle of Escherichia coli. J Bacteriol (1972) 0.91
Aberrant p27Kip1 promoter methylation in malignant melanoma. Oncogene (2000) 0.91
Melanoma-associated antigens recognized by cytotoxic T lymphocytes. APMIS (1998) 0.90
Plasminogen activating enzyme in cultured glioblastoma cells. An immunofluorescence study with monoclonal antibody. J Histochem Cytochem (1982) 0.90
Expression of transporter associated with antigen processing 1 and 2 (TAP1/2) in malignant melanoma cell lines. Int J Cancer (1997) 0.89
The selection of somatic cell hybrids between human lymphoma cell lines. Somatic Cell Genet (1976) 0.89
Reactivation of chick erythrocyte nuclei after fusion with enucleated cells. Somatic Cell Genet (1975) 0.89
Somatic cell hybrids between human lymphoma lines. II. Spontaneous and induced patterns of the Epstein-Barr virus (EBV) cycle. Int J Cancer (1976) 0.89
Escape from host-antitumor immunity. Crit Rev Oncog (1997) 0.88
An assay for peptide binding to HLA-Cw*0102. Tissue Antigens (1999) 0.87
Transfection of glioma cells with the neural-cell adhesion molecule NCAM: effect on glioma-cell invasion and growth in vivo. Int J Cancer (1994) 0.86
Expression of immunoglobulin synthesis in human myeloma x non-lymphoid cell heterokaryons: evidence for negative control. Cell Differ (1976) 0.86
A one-step DGGE scanning method for detection of mutations in the K-, N-, and H-ras oncogenes: mutations at codons 12, 13 and 61 are rare in B-cell non-Hodgkin's lymphoma. Int J Cancer (1997) 0.86
Higher-order structure of mitotic chromosomes. Cold Spring Harb Symp Quant Biol (1978) 0.86
Preferential usage of T-cell receptor alpha beta variable regions among tumor-infiltrating lymphocytes in primary human malignant melanomas. Int J Cancer (1994) 0.86
Complete scanning of the CDK4 gene by denaturing gradient gel electrophoresis: a novel missense mutation but low overall frequency of mutations in sporadic metastatic malignant melanoma. Int J Cancer (1997) 0.85
Analysis of a highly immunodominant epitope in the human immunodeficiency virus type 1 transmembrane glycoprotein, gp41, defined by a human monoclonal antibody. J Virol (1990) 0.85
Cytotoxic T-lymphocyte clones, established by stimulation with the HLA-A2 binding p5365-73 wild type peptide loaded on dendritic cells In vitro, specifically recognize and lyse HLA-A2 tumour cells overexpressing the p53 protein. Scand J Immunol (2000) 0.85
Influenza virus-specific murine T cell hybridomas which recognize virus hemagglutinin in conjunction with H-2d and display helper functions for B cells. Curr Top Microbiol Immunol (1982) 0.85
Generation of human-melanoma-specific T lymphocyte clones defining novel cytolytic targets with panels of newly established melanoma cell lines. Cancer Immunol Immunother (1995) 0.85
Assembly of the T-cell antigen receptor. Participation of the CD3 omega chain. J Immunol (1993) 0.85
Transfer of tRNAs to somatic cells mediated by Sendai-virus-induced fusion. Proc Natl Acad Sci U S A (1976) 0.84
Tumor infiltrating lymphocytes in melanoma comprise high numbers of T-cell clonotypes that are lost during in vitro culture. Clin Immunol (2000) 0.84
Replication and expression in mammalian cells of transfected DNA; description of an improved erythrocyte ghost fusion technique. Nucleic Acids Res (1983) 0.84
Antigen-specific primary immune response of human B-lymphocytes after in vitro immunization with GM3 ganglioside. Hum Antibodies Hybridomas (1995) 0.83
Human lymphoma-lymphoma hybrids and lymphoma-leukemia hybrids. II. Epstein-Barr virus induction patterns. J Natl Cancer Inst (1982) 0.83
Concurrent disruption of p16INK4a and the ARF-p53 pathway predicts poor prognosis in aggressive non-Hodgkin's lymphoma. Leukemia (2000) 0.83
Analysis of T cell receptor alpha beta variability in lymphocytes infiltrating melanoma primary tumours and metastatic lesions. Cancer Immunol Immunother (1994) 0.83
Expression of CD94/NKG2 subtypes on tumor-infiltrating lymphocytes in primary and metastatic melanoma. J Invest Dermatol (2000) 0.82
The immunogenic properties of melanoma-associated antigens recognized by cytotoxic T lymphocytes. Exp Clin Immunogenet (1998) 0.82
Immunological relationship between the fast-acting plasminogen activator inhibitors from plasma, blood platelets and endothelial cells demonstrated with a monoclonal antibody against an inhibitor from placenta. Thromb Haemost (1986) 0.82
Characterisation of tumour infiltrating lymphocytes and correlations with immunological surface molecules in colorectal cancer. Eur J Cancer (1999) 0.82
A comparison of flow cytometry and immunohistochemistry in human colorectal cancers. APMIS (1998) 0.82
Expression of SV40 T antigen during the cell cycle of sv40-transformed cells. Int J Cancer (1975) 0.82
Escape mechanisms in tumor immunity: a year 2000 update. Crit Rev Oncog (2000) 0.82
Recognition of insulin on MHC-class-II-expressing L929 cells by antibody and T cells. Res Immunol (1989) 0.82
Primary cutaneous B-cell lymphoma: a clinical, histological, phenotypic and genotypic study of 21 cases. Br J Dermatol (2000) 0.82
Establishment of gp100 and MART-1/Melan-A-specific cytotoxic T lymphocyte clones using in vitro immunization against preselected highly immunogenic melanoma cell clones. Cancer Immunol Immunother (1999) 0.81
Differential modulation by interferon gamma of the sensitivity of human melanoma cells to cytolytic T cell clones that recognize differentiation or progression antigens. Cancer Immunol Immunother (1996) 0.81
Plasminogen activator inhibitor-1 is the primary inhibitor of tissue-type plasminogen activator in pregnancy plasma. Thromb Haemost (1987) 0.81
A T-helper cell x Molt4 human hybridoma constitutively producing B-cell stimulatory and inhibitory factors. Lymphokine Res (1986) 0.81
The role of endogenous peptides in the direct pathway of alloreactivity to human MHC class II molecules expressed on CHO cells. Immunol Rev (1996) 0.81
Recombinant interleukin-2 and lymphokine-activated killer cell treatment of advanced bladder cancer: clinical results and immunological effects. Cancer Res (1992) 0.81
Lectin purified human class I MHC-derived peptides: evidence for presentation of glycopeptides in vivo. Tissue Antigens (2000) 0.81
Interleukin-2 dose, blood monocyte and CD25+ lymphocyte counts as predictors of clinical response to interleukin-2 therapy in patients with renal cell carcinoma. Cancer Immunol Immunother (1991) 0.81
In vivo and in vitro generation of a new altered HLA phenotype in melanoma-tumour-cell variants expressing a single HLA-class-I allele. Int J Cancer (1998) 0.80
Phase I study of single, escalating doses of a superantigen-antibody fusion protein (PNU-214565) in patients with advanced colorectal or pancreatic carcinoma. J Immunother (2000) 0.80
Cells and cytokines in immunotherapy and gene therapy of cancer. Crit Rev Oncog (1999) 0.80
T cell-independent B cell response to self-monosialogangliosides: primary response monoclonal antibodies. Hybridoma (1995) 0.79
Kinetics and function of peritoneal-exudate cells during local IL-2 gene-therapy of cancer. Int J Oncol (1994) 0.79
Human lymphoma-lymphoma hybrids and lymphoma-leukemia hybrids. I. Isolation, characterization, cell surface markers, and B-cell markers. J Natl Cancer Inst (1982) 0.79
Detection of mutations in GC-rich DNA by bisulphite denaturing gradient gel electrophoresis. Nucleic Acids Res (1998) 0.79
Deficiency of malic enzyme: a possible marker for malignancy in lymphoid cells. Ann Hum Genet (1981) 0.78